This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
scPharmaceuticals 대차대조표 건전성
재무 건전성 기준 점검 0/6
scPharmaceuticals 의 총 주주 지분은 $-21.3M 이고 총 부채는 $51.2M, 이는 부채 대 자기자본 비율을 -240.2% 로 가져옵니다. 총자산과 총부채는 각각 $80.3M 및 $101.6M 입니다.
핵심 정보
-240.20%
부채/자본 비율
US$51.20m
부채
| 이자보상배율 | n/a |
| 현금 | US$41.09m |
| 자본 | -US$21.32m |
| 총부채 | US$101.57m |
| 총자산 | US$80.26m |
최근 재무 건전성 업데이트
분석 기사 • Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Recent updates
내러티브 업데이트 • Aug 26
Outpatient Care Shift And Medicare Redesign Will Expand Patient Access
The consensus price target for scPharmaceuticals was raised to $16.75 as analysts reflect the MannKind acquisition at $5.35 per share plus a potential $1.00 CVR, with bullish outlooks on CVR payout likelihood and capped upside from the deal terms. Analyst Commentary Acquisition of scPharmaceuticals by MannKind at $5.35 per share in cash plus a contingent value right (CVR) worth up to $1.00 per share, bringing total potential consideration to $6.35 per share.분석 기사 • Jul 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shares have continued their recent momentum with a 26% gain in the last month...분석 기사 • Jun 02
Further Upside For scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Could Introduce Price Risks After 40% Bounce
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shares have had a really impressive month, gaining 40% after a shaky period...분석 기사 • May 27
Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable
Key Insights scPharmaceuticals will host its Annual General Meeting on 3rd of June Salary of US$663.8k is part of CEO...새로운 내러티브 • May 13
FDA Approval And Medicare Redesign Will Transform CKD Treatment Access
FDA approval of FUROSCIX for CKD patients significantly expands the market, boosting revenue potential and enhancing growth opportunities.분석 기사 • Apr 04
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • Nov 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Unfortunately for some shareholders, the scPharmaceuticals Inc. ( NASDAQ:SCPH ) share price has dived 26% in the last...분석 기사 • Nov 18
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term
Today is shaping up negative for scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders, with the analysts delivering a...분석 기사 • Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders are no doubt pleased to see that the share price has bounced 26% in...분석 기사 • Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
scPharmaceuticals Inc. ( NASDAQ:SCPH ) just released its latest full-year results and things are looking bullish. It...분석 기사 • Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Oct 20
scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Summary After two CRLs, FUROSCIX has finally received FDA approval. This treatment could be a game-changer in the treatment of heart failure, allowing certain patients to avoid costly hospitalizations altogether and simply self-administer treatment at home. The stock has been very volatile in the days following approval, but investors should focus on the compelling long-term story. NOTE: For investors new to this stock and the condition of heart failure (“HF”), I encourage you to listen to the Key Opinion Leader (“KOL”) webcast from September 29, 2020. While the physicians that joined President and CEO John Tucker in the webcast— Dr. Nihar Desai (Yale School of Medicine) and Dr. Dan Bensimhon (Cone Health)— are paid consultants of SCPH, it does not invalidate the points they make, nor the validity of the investment opportunity. The slides from the December 3, 2020 Evercore ISI Virtual HealthCONx Conference presentation (download here) are also helpful in understanding the investment thesis (unfortunately, the webcast for this event is not currently active). The majority of the content in this article is supported by what was discussed at these two events. It has been a long wait of 4+ years for investors in scPharmaceuticals (SCPH). The first CRL for lead drug candidate FUROSCIX was received in June 2018, and then a second CRL was received in December 2020. But finally, before the market opened on Monday, October 10, the company announced that FUROSCIX had gotten a thumbs up from the FDA. Though FDA approvals are usually expected to boost the stock price, this stock has been volatile in the days immediately following the approval announcement. On the Monday that the announcement was made, it finished down about 14%, before jumping up over 30% on Tuesday. Other than a possible “buy the rumor, sell the news” explanation, I think the main reason the stock was down on Monday was because of the new $100M debt financing agreement that was announced alongside the FDA approval. However, I think the market overreacted to the news of the new debt facility. If we look at the 2Q22 10-Q filing (pg 10), we can see that the existing “2019 Loan Agreement” was at an interest rate of the higher of (i) LIBOR plus 7.95% or (ii) 10.18% (this loan agreement was for up to $20M, and as of June 30, there was $12.5M drawn, which will be repaid in full using the new debt facility). The new $100M debt agreement with Oaktree Capital Management bears interest at the 3-month secured overnight financing rate (SOFR) plus 8.75%, and the interest rate is capped at 11.75%. Considering the fact that we are in a much higher interest rate environment compared to 2019, the new terms do not seem so unfavorable. The market might also have been disappointed because the new financing agreement confirmed that SCPH will not partner to commercialize FUROSCIX, but instead will commercialize on its own. It always adds an additional risk factor when a biotech that has been specializing in R&D for several years decides to build out its own salesforce rather than partner with an established pharmaceutical company and simply collect a royalty from net sales of its drug. If it goes well for SCPH, then they will end up keeping all of the net sales rather than just a percentage from a licensing agreement. But if it doesn’t go well, it can be an expensive undertaking, as SCPH will bear all of the commercialization costs on its own. This late in the process, however, I don’t think it should come as a surprise that SCPH did not find a partner to market FUROSCIX. Management has made comments during presentations at conferences over the past few years that discussed the salesforce size they thought would be required to reach a majority of the target patients, and I think these statements indicated a likelihood that they would commercialize on their own. What I think is most useful for investors to focus on at this point is not the stock price volatility, but rather the compelling market opportunity for FUROSCIX. 2020 Evercore ISI HealthCONx Conference Presentation 2020 Evercore ISI HealthCONx Conference Presentation Congestive heart failure (also known simply as heart failure) occurs when a patient’s heart is unable to pump blood as forcefully as it should, often causing blood back-ups. Fluid build-up can leak out of blood vessels and swell into other tissues (known as edema, or swelling due to water retention). If there is fluid build-up in the lungs, it can cause shortness of breath and difficulty breathing. Patients can also experience symptoms such as swelling of the belly and overall weight gain. To treat this excess fluid build-up, the medical community has for decades turned to diuretics, which are compounds that increase urine flow. There are three main types of diuretics (loop, thiazide, and potassium-sparing), categorized by their mechanism of action. Of the loop diuretics, furosemide (which goes by the brand name Lasix) is the most commonly prescribed oral and parenteral treatment. At prior events, the SCPH CEO has explained that in the US, there are 6.5M HF patients taking oral Lasix as a maintenance therapy, and that most of them are doing just fine. However, every year, there are approximately 4M instances in which oral Lasix is not enough, as the patients do not see a reduction in swelling in their extremities and body weight. When this occurs, cardiologists tend to double the oral dose, and sometimes even prescribe Zaroxolyn (metolazone), which is a thiazide diuretic. Unfortunately, Zaroxolyn can come with some unfavorable side effects, such as damage to the kidneys. For some patients placed on a new course of treatment, the swelling recedes, and in due time, they can go back to their original oral Lasix maintenance therapy. For patients that do not see a reduction in swelling, their physician will likely decide that they are in need of an even stronger diuretic. This almost always means a treatment of IV Lasix, which requires either a trip to a medical facility or a home visit by a health care practitioner. The benefit that IV Lasix has over oral Lasix, and the reason it is used as a treatment of last resort, is that it offers 100% bioavailability. Bioavailability is simply how much of an administered substance is able to be absorbed by the circulatory system and reach its target area. The higher the bioavailability, the more effective a drug tends to be. This YouTube video (Pharmacology - Loop Diuretics - Furosemide (Lasix) IV in Heart Failure - Dr. Busti) does a good job explaining why oral diuretics are just not enough in certain high-risk HF patients. While I encourage you to watch it in its entirety, if you fast forward to minute 9:00, there is a table that shows the bioavailability of oral Lasix to be only 50%-70% in a normal patient. This means that 30%-50% of the dose never even makes it to its intended targets—and this is in normal patients, with the bioavailability decreasing depending on the health severity of the patient. What investors should take from all of this is that for high-risk HF patients, medical providers cannot take the risk of continuing to go with oral Lasix, and instead need something that guarantees 100% bioavailability. This has always meant IV Lasix—until now. What SCPH has been able to show is that FUROSCIX (a subcutaneous administration of furosemide) is bioequivalent to IV Lasix, in that it offers the same amount of fluid reduction over the course of 6 hours.Seeking Alpha • Oct 10
FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
The U.S. Food and Drug Administration (FDA) approved scPharmaceuticals (NASDAQ:SCPH) Furoscix's to treat congestion due to fluid overload in adults with New York Heart Association Class 2/3 chronic heart failure. Furoscix, a proprietary formulation of furosemide delivered via an On-Body Infusor, is the first and only FDA-approved subcutaneous loop diuretic which delivers IV equivalent diuresis at home via the Furoscix Infusor, the company said in an Oct. 10 press release. In a study Furoscix showed 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide, scPharmaceuticals noted. Furoscix is not indicated for use in emergency situations or in patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of the drug, the company added. The commercial launch is planned for Q1 2023 by scPharmaceuticals. In a separate release, the company said it signed an agreement for a $100M debt facility. SCPH -6.83% to $4.64 premarket분석 기사 • Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 26
scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
The FUROSCIX NDA resubmission is expected to occur during 4Q21. Continued data releases demonstrate the cost-reducing value proposition of FUROSCIX. The liquidity position is very favorable.재무 상태 분석
단기부채: SCPH 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.
장기 부채: SCPH는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.
부채/자본 비율 추이 및 분석
부채 수준: SCPH 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.
부채 감소: SCPH는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.
대차대조표
현금 보유 기간 분석
과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.
안정적인 현금 활주로: SCPH 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.
예측 현금 활주로: SCPH 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.
건전한 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/10/08 18:54 |
| 종가 | 2025/10/06 00:00 |
| 수익 | 2025/06/30 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
scPharmaceuticals Inc.는 6명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |